Jeffrey Tong
Chairman at Ambys Medicines, Inc.
Profile
Jeffrey K.
Tong is currently the Executive Chairman at Ambys Medicines, Inc., Chairman at Septerna, Inc., Director at Maze Therapeutics, Inc., Director at Asher Biotherapeutics, Inc., Director at Regeneration NewCo, Inc., Director at Terremoto Biosciences, Inc., Director at Rapport Therapeutics, Inc., and a Partner at Third Rock Ventures LLC since 2016.
Previously, he served as the President & Chief Executive Officer at Nora Therapeutics, Inc. from 2010 to 2015, Chairman at Delinia, Inc. from 2016 to 2017, Independent Director at Nurix Therapeutics, Inc. from 2018 to 2022, and Vice President-Corporate & Product Development at Infinity Pharmaceuticals, Inc. He also worked as a Consultant at McKinsey & Co., Inc. Dr. Tong holds graduate and doctorate degrees from Harvard University, a graduate degree from Harvard Medical School, and an undergraduate degree from Harvard College.
Jeffrey Tong active positions
| Companies | Position | Start |
|---|---|---|
Third Rock Ventures LLC
 Third Rock Ventures LLC Investment ManagersFinance Third Rock Ventures LLC (Third Rock Ventures) is a venture capital firm founded in 2007 by Mark Levin, Robert Tepper, Kevin Starr and Nick Leschly. The firm is headquartered in Boston, Massachusetts. | Private Equity Investor | 01/01/2016 |
Ambys Medicines, Inc.
 Ambys Medicines, Inc. Pharmaceuticals: MajorHealth Technology Ambys Medicines, Inc. develops regenerative medicine therapies for serious liver diseases. The company was founded by Martin Burke, Markus Grompe, Juan Carlos Izpisua Belmonte and Holger Willenbring and is headquartered in South San Francisco, CA. | Chairman | 13/12/2018 |
Maze Therapeutics, Inc.
 Maze Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Maze Therapeutics, Inc. is a is a biopharmaceutical company, which engages in the development of portfolio of therapeutic candidates for a number of genetically defined diseases. It focuses on translating genetic insights into new medicines by utilizing an approach that combines the analysis of large-scale human genetics data, cutting-edge functional genomics, and an array of drug discovery approaches. The company was founded by Mark Daly, Aaron D. Gitler, Stephen Elledge, Sekar Kathiresan, and Jonathan S. Weissman in 2018 and is headquartered in San Francisco, CA. | Director/Board Member | - |
Regeneration NewCo, Inc.
 Regeneration NewCo, Inc. Financial ConglomeratesFinance Regeneration NewCo, Inc. operates as a development stage company. The company is headquartered in South San Francisco, CA. | Director/Board Member | - |
Asher Biotherapeutics, Inc.
 Asher Biotherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Asher Biotherapeutics, Inc. engages in the research and development of immunotherapy for cancer. The company was founded by Ivana Djuretic and Andy Yeung in 2019 and is headquartered in South San Francisco, CA. | Director/Board Member | - |
Septerna, Inc.
 Septerna, Inc. Pharmaceuticals: MajorHealth Technology Septerna, Inc. is a biotechnology company located in an undisclosed location. The American company is focused on developing novel, oral small molecule drugs that target the entire class of G protein-coupled receptors (GPCRs). The company's Native Complex™ platform allows for the rapid application of new technologies for industrial-scale drug discovery to address both validated GPCRs and many GPCRs that have been undruggable and unexploited to date. Septerna is building a pipeline of GPCR-targeted, oral small molecule drug candidates, led by its program targeting the parathyroid hormone 1 receptor (PTH1R) for the treatment of hypoparathyroidism. The company was founded in 2022 by scientific founders who have made groundbreaking GPCR discoveries, including Patrick Sexton, Arthur Christopoulos, Robert Joseph Lefkowitz, and Jeffrey T. Finer. Jeffrey T. Finer has been the CEO since incorporation. | Chairman | - |
Terremoto Biosciences, Inc.
 Terremoto Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Terremoto Biosciences, Inc. is a drug discovery and development company that creates highly targeted, small molecule medicines with unmatched selectivity, potency, and efficacy to deliver superior therapeutic benefit to patients. The company is based in San Francisco, CA. Terremoto is supported by leading investors, including OrbiMed, Third Rock Ventures, EcoR1 Capital, Novo Holdings, and Cormorant Capital. The company aims to expand the universe of drug targets and improve existing medicines by unleashing the power of covalent chemistry. Terremoto was founded by Peter A. Thompson and Matthew P. Jacobson, and Peter A. Thompson has been the CEO since incorporation. | Director/Board Member | - |
Rapport Therapeutics, Inc.
 Rapport Therapeutics, Inc. BiotechnologyHealth Technology Rapport Therapeutics, Inc. is an American clinical-stage biotechnology company that focuses on discovering and developing medicines for neurological disorders. The CEO of the company is Abraham N. Ceesay. | Director/Board Member | - |
Former positions of Jeffrey Tong
| Companies | Position | End |
|---|---|---|
| NURIX THERAPEUTICS, INC. | Director/Board Member | 05/05/2022 |
| ░░░░░░░░ ░░░░ ░░░░░░░ ░░░░░░░ | ░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | - |
| ░░░░░░░░ ░░░░░ ░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
| ░░░░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
Training of Jeffrey Tong
| Harvard University | Doctorate Degree |
| Harvard Medical School | Graduate Degree |
| Harvard College | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| NURIX THERAPEUTICS, INC. | Health Technology |
| INFINITY PHARMACEUTICALS, INC. | Health Technology |
| Private companies | 11 |
|---|---|
McKinsey & Co., Inc.
 McKinsey & Co., Inc. Miscellaneous Commercial ServicesCommercial Services McKinsey & Co., Inc. provides management consulting services. It specializes in design, marketing and sales, analytics, operations, transformation and restructuring, risk, strategy and corporate finance, and sustainability and resource productivity. The company was founded by James O. McKinsey in 1926 and is headquartered in New York, NY. | Commercial Services |
Nora Therapeutics, Inc.
 Nora Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Nora Therapeutics, Inc. develops therapeutics to address clinical unmet needs in reproductive medicine. Its's lead product NT100, seeks to improve pregnancy outcomes in women undergoing in vitro fertilization or who have suffered recurrent spontaneous miscarriages. The company was founded by Darryl L. Carter and Chris B. McClain in 2007 and is headquartered in Palo Alto, CA. | Health Technology |
Delinea, Inc. (United States)
 Delinea, Inc. (United States) BiotechnologyHealth Technology Delinia, Inc. operates as a biotechnology company that develops novel therapeutics for the treatment of autoimmune diseases. Its main program is a molecule that potentiates and expands Regulatory T Cells, powerful immune cells that are critical to maintaining self-tolerance and immune system homeostasis. Tregs are critically important immune regulatory cells in the path physiology of cancer and autoimmune disease. Delinia was founded by Michael Rosenblum and Jeffrey Greve in 2015 and is headquartered in Summit, NJ. | Health Technology |
Ambys Medicines, Inc.
Ambys Medicines, Inc. Pharmaceuticals: MajorHealth Technology Ambys Medicines, Inc. develops regenerative medicine therapies for serious liver diseases. The company was founded by Martin Burke, Markus Grompe, Juan Carlos Izpisua Belmonte and Holger Willenbring and is headquartered in South San Francisco, CA. | Health Technology |
Maze Therapeutics, Inc.
Maze Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Maze Therapeutics, Inc. is a is a biopharmaceutical company, which engages in the development of portfolio of therapeutic candidates for a number of genetically defined diseases. It focuses on translating genetic insights into new medicines by utilizing an approach that combines the analysis of large-scale human genetics data, cutting-edge functional genomics, and an array of drug discovery approaches. The company was founded by Mark Daly, Aaron D. Gitler, Stephen Elledge, Sekar Kathiresan, and Jonathan S. Weissman in 2018 and is headquartered in San Francisco, CA. | Commercial Services |
Asher Biotherapeutics, Inc.
Asher Biotherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Asher Biotherapeutics, Inc. engages in the research and development of immunotherapy for cancer. The company was founded by Ivana Djuretic and Andy Yeung in 2019 and is headquartered in South San Francisco, CA. | Commercial Services |
Regeneration NewCo, Inc.
Regeneration NewCo, Inc. Financial ConglomeratesFinance Regeneration NewCo, Inc. operates as a development stage company. The company is headquartered in South San Francisco, CA. | Finance |
Septerna, Inc.
Septerna, Inc. Pharmaceuticals: MajorHealth Technology Septerna, Inc. is a biotechnology company located in an undisclosed location. The American company is focused on developing novel, oral small molecule drugs that target the entire class of G protein-coupled receptors (GPCRs). The company's Native Complex™ platform allows for the rapid application of new technologies for industrial-scale drug discovery to address both validated GPCRs and many GPCRs that have been undruggable and unexploited to date. Septerna is building a pipeline of GPCR-targeted, oral small molecule drug candidates, led by its program targeting the parathyroid hormone 1 receptor (PTH1R) for the treatment of hypoparathyroidism. The company was founded in 2022 by scientific founders who have made groundbreaking GPCR discoveries, including Patrick Sexton, Arthur Christopoulos, Robert Joseph Lefkowitz, and Jeffrey T. Finer. Jeffrey T. Finer has been the CEO since incorporation. | Health Technology |
Terremoto Biosciences, Inc.
Terremoto Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Terremoto Biosciences, Inc. is a drug discovery and development company that creates highly targeted, small molecule medicines with unmatched selectivity, potency, and efficacy to deliver superior therapeutic benefit to patients. The company is based in San Francisco, CA. Terremoto is supported by leading investors, including OrbiMed, Third Rock Ventures, EcoR1 Capital, Novo Holdings, and Cormorant Capital. The company aims to expand the universe of drug targets and improve existing medicines by unleashing the power of covalent chemistry. Terremoto was founded by Peter A. Thompson and Matthew P. Jacobson, and Peter A. Thompson has been the CEO since incorporation. | Health Technology |
Rapport Therapeutics, Inc.
Rapport Therapeutics, Inc. BiotechnologyHealth Technology Rapport Therapeutics, Inc. is an American clinical-stage biotechnology company that focuses on discovering and developing medicines for neurological disorders. The CEO of the company is Abraham N. Ceesay. | Health Technology |
Third Rock Ventures LLC
Third Rock Ventures LLC Investment ManagersFinance Third Rock Ventures LLC (Third Rock Ventures) is a venture capital firm founded in 2007 by Mark Levin, Robert Tepper, Kevin Starr and Nick Leschly. The firm is headquartered in Boston, Massachusetts. | Finance |
- Stock Market
- Insiders
- Jeffrey Tong
